NCT05433116
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05433116
Title Pembrolizumab and Lenvatinib After Definitive Chemoradiation of Locally Advanced HNSCC
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Erlangen-Nuernberg Medical School
Indications
Therapies
Age Groups: adult | senior
Covered Countries DEU


No variant requirements are available.